Yagil Yoram, Yagil Chana
Department of Nephrology and Hypertension, Faculty of Health Sciences, Ben-Gurion University, Barzilai Medical Center, Ashkelon, Israel.
Transpl Immunol. 2002 May;9(2-4):203-9. doi: 10.1016/s0966-3274(02)00022-9.
The advent of the genomic era has brought about several new fields of study, one of them being pharmacogenomics, which seeks to link drug treatment (pharmaco-) with the individual's genetic make-up (genomics). Pharmacogenomics holds many promises for improved treatment of a large variety of medical conditions, including immunosuppression for organ transplantation and autoimmune disease. Many of these promises have, however, not yet been fulfilled. In this brief overview of the subject, we attempt to provide insights into the evolving field of pharmacogenomics and discuss some of its potential benefits and promises, technological tools used by pharmacogenomics, the reasons for delays in breakthroughs in the field, and the relevance of pharmacogenornics to immunosuppression.
基因组时代的到来催生了几个新的研究领域,其中之一是药物基因组学,它旨在将药物治疗(药物)与个体的基因构成(基因组学)联系起来。药物基因组学有望改善多种医疗状况的治疗效果,包括器官移植和自身免疫性疾病的免疫抑制。然而,这些承诺中的许多尚未实现。在对该主题的简要概述中,我们试图深入了解药物基因组学这一不断发展的领域,讨论其一些潜在益处和前景、药物基因组学所使用的技术工具、该领域突破延迟的原因以及药物基因组学与免疫抑制的相关性。